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Abstract
Osteoarthritis (OA) is a degenerative disease involving chondro-
cytes, cartilage and other joint tissues, and has a number of
underlying causes, including both biochemical and mechanical
factors. Although proinflammatory factors including nitric oxide
(NO) are associated with OA, there is recent evidence suggesting
that NO and its redox derivatives may also play protective roles in
the joint. However, the mechanisms that underlie the development
and progression of OA are not completely understood. Experi-
ments have demonstrated that NO plays a catabolic role in the
development of OA and mediates the inflammatory response, is
involved in the degradation of matrix metalloproteinases, inhibits
the synthesis of both collagen and proteoglycans, and helps to
mediate apoptosis. However, there is also evidence that in cultured
chondrocytes the addition of exogenous NO may inhibit proinflam-
matory activation by preventing the nuclear localization of the trans-
cription factor nuclear factor-κB, whereas the presence of
peroxynitrite - a redox derivative of NO - appears to enhance the
inflammatory response by sustaining the nuclear localization of
nuclear factor-κB. In addition, under some conditions exogenous
NO can stimulate collagen synthesis in cultured rat fibroblasts and
human tendon cells. The protective roles of NO in multiple cell
types, along with the opposing activities in cultured chondrocytes,
suggest that NO may play additional protective roles in
chondrocyte function. NO and its derivatives have a similarly
complicated involvement in nociception and pain, which may
contribute to the functional disability of OA. Further research may
help to elucidate a potential role for NO-donating agents in the
management of OA.
Introduction
Osteoarthritis (OA) is a complex disease with a number of
underlying biochemical and physical causes. Despite the
worldwide prevalence of OA, there are still questions about
the events that cause OA, making it difficult to identify
potential disease-modifying targets. Proinflammatory media-
tors, including nitric oxide (NO), IL-1, tumor necrosis factor
(TNF)-α, and prostaglandins, are all over-produced in
chondrocytes harvested from patients with OA (as reviewed
by Pelletier and coworkers [1]) and help to perpetuate the
inflammatory process. NO has also long been considered to
be a catabolic factor that contributes to the OA disease
pathology by mediating a number of processes, including
apoptosis, and perpetuating the expression of proinflam-
matory cytokines [1]. High concentrations of nitrites and
nitrates have been found in the synovial fluid and plasma of
patients with arthritis [2]. Although increased levels of NO
activity have been found in the synovial fluid of patients with
rheumatoid arthritis [3,4] and juvenile idiopathic arthritis [5],
analyses of the NO content in the synovial fluid of patients
with OA have yielded contradictory findings [6,7]. NO
concentrations are, however, significantly increased in the
synovial fluid of a canine OA model [8]. These findings, in
combination with experiments described below, contribute to
the prevailing hypothesis that NO is a proinflammatory and
proapoptotic factor that, when present in excess, is
detrimental to the joint and contributes to OA pathogenesis.
Despite the evidence that NO is primarily a catabolic factor in
OA, newer studies have suggested that this view of NO may
be too simplistic. Instead, there is evidence that the effects of
NO may be concentration and/or time dependent. In addition,
studies suggest that NO and its reactive oxygen species
(ROS) derivatives may also have opposing effects, both
destructive and protective. Finally, there is a small but
growing body of literature demonstrating that NO has
beneficial effects on other cell types, including tendons and
osteoblasts, which could also potentially be present in
chondrocytes. In addition, NO and its derivatives also play
critical roles in both the production and reduction of noci-
ception and pain, which is the primary cause of functional
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disability in OA. These studies suggest that NO donors could
be an asset in the treatment of OA. This article briefly reviews
the literature describing a catabolic role for NO in cartilage
and chondrocytes, and then summarizes existing studies that
may suggest alternative roles for NO in the joint.
Introduction to nitric oxide
NO is synthesized in mammalian cells by the conversion of
L-arginine to L-citrulline plus NO. This reaction is catalyzed by
one of three isoforms of nitric oxide synthase (NOS). Two of
the NOS enzymes, namely endothelial NOS and neuronal
NOS, are calcium dependent and constitutively produce
relatively low levels of NO. The inducible isoform (inducible
NOS [iNOS]) is expressed for a longer period of time upon
activation by a variety of factors, including the inflammatory
cytokines TNF-α and lipopolysaccharide (reviewed by
Weinberg and coworkers [9]). Once synthesized, NO can
diffuse within the same cell or neighboring cells, where it
binds to the heme group of soluble guanylyl cyclase to
generate cGMP from GTP [10]. Activated cGMP then binds
specifically to target proteins including transcription factors,
protein kinases and phosphodiesterases to elicit downstream
effects. However, NO can also act in a cGMP-independent
manner, for example by directly modifying proteins or
contributing to the oxidation of proteins and lipids, further
increasing the complexity and number of potential roles for
NO in normal and pathophysiologic functions [11].
In addition to signaling by the NO molecule alone, ROS
including superoxide, hydrogen peroxide, and peroxynitrite
are also involved in mediating cellular functions. It is clear that
these molecules also have specific cellular functions and play
specific roles in pathogenesis. Peroxynitrite is generated by
the combination of NO and superoxide, and it contributes to
a number of destructive events in cartilage, including apop-
tosis [12,13]. Joint fluid analysis in patients with OA identified
significantly lower concentrations of the superoxide scavenger
enzyme extracellular superoxide dismutase (SOD), suggest-
ing an increase in oxidative damage may contribute to
damage caused by OA [14]. Like NO, however, studies have
suggested that the role of reactive nitrogen oxide species
(RNOS) in the cell is complex, and newly discovered
functions are still being described in the literature.
Although this review focuses primarily on the role played by
NO and its redox derivatives in the pathogenesis of OA, NO
is also involved in normal development. For example,
experiments in chick growth plate chondrocytes illustrated
that all three isoforms of NOS are expressed and active in the
growth plate (Figure 1) [15], and we have detected both
endothelial NOS and neuronal NOS mRNA in chondrocytes
of patients with OA [16]. NO donors increased alkaline
phosphatase activity, and transfection of the endothelial NOS
isoform increased collagen type X expression. Conversely,
incubation with NOS inhibitors reversed the increase in
alkaline phosphatase activity, whereas cGMP inhibitors
reversed the increases in alkaline phosphatase activity and
collagen expression, demonstrating that NO helps to mediate
the terminal differentiation of chondrocytes. These experi-
ments show that NO helps regulate two steps in chondrocyte
development, namely expression of collagen type X as well as
alkaline phosphatase activity [15], illustrating just one
example of a nonpathological role for NO.
Catabolic role of nitric oxide in chondrocytes
As mentioned in the Introduction section (above), there are
numerous examples of the catabolic effects of NO on cultured
chondrocytes and cartilage. Chondrocytes from patients with
OA express iNOS in the superficial zone [16,17], reflecting an
increase in NO during the OA disease process. NO also
inhibits the synthesis of both proteoglycans and collagen in
rabbit cartilage cultures [18] and has been shown to
upregulate the synthesis of matrix metalloproteinases in a
cGMP-dependent manner [19,20]; both of these actions
contribute to destruction of the extracellular matrix. In addition,
NO mediates the expression of proinflammatory cytokines,
including IL-18, and the synthesis of the IL-1-converting
enzyme, a caspase required for the maturation of both IL-1
and IL-18 [21]. These findings support the conclusion that NO
is primarily a catabolic factor in OA.
However, not all chondrocytes respond identically to pro-
inflammatory stimuli, and neither do all chondrocytes produce
equivalent amounts of NO when they are exposed to the
same stimulus. This suggests that a straightforward catabolic
role for NO in the joint may be too simplistic. Häuselmann
and colleagues [22] harvested chondrocytes from different
zones of articular cartilage and observed that different layers
of cartilage generated varying amounts of NO in response to
IL-1 stimulation. Specifically, chondrocytes from the super-
ficial layer of normal human cartilage synthesized two to three
times as much NO as did those from the deep zone of the
same cartilage sample. IL-1 stimulation inhibited proteoglycan
synthesis equally in both zones. However, in the presence of
the NOS inhibitor NG-monomethyl-L-arginine (L-NMA), the IL-
1-induced inhibition of proteoglycan synthesis was
completely reversed in the deep zone whereas only a partial
effect was observed in the superficial zone. In addition,
exposure to L-NMA and IL-1 together reduced the metabolic
half-life of proteoglycans in the deep and superficial zones,
despite the differing effects on proteoglycan inhibition. Finally,
the authors observed that NO production in response to IL-1
stimulation declined with age. These findings led the authors
to suggest that NO may not mediate extracellular matrix
turnover identically throughout articular cartilage and, perhaps,
plays a protective role in proteoglycan catabolism [22].
Intriguingly, chondrocytes not only respond differently to NO
based on their location in the cartilage, but different effects
on cartilage can be elicited depending on the method used to
inhibit inflammation. Bezerra and coworkers [23] examined
the effects of NO and peroxynitrite in zymosan-inducedPage 3 of 7
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arthritis, and found that the addition of both NO and peroxy-
nitrite induced inflammation (as measured by histopathology
and the glycosaminoglycan content of the cartilage). Further-
more, when a nonselective NOS inhibitor or a selective iNOS
inhibitor was added, the synovitis was improved but the
glycosaminoglycan loss was enhanced. This indicates that
although blocking NO production helps to decrease inflam-
mation, cartilage damage is enhanced. Finally, when the
peroxynitrite scavenger uric acid was added, both the
synovitis and glycosaminoglycan loss was ameliorated,
suggesting that inhibiting peroxynitrite production may be a
more effective target for protecting against inflammation and
cartilage loss in this arthritis model [23]. Again, these
experiments, combined with the different behavior associated
with chondrocyte location in the joint, suggest that the role
played by NO in the joint may be more complicated than
previously understood and that more research is needed.
Nitric oxide and apoptosis
In addition to contributing to the breakdown of the
extracellular matrix, NO also mediates apoptosis. Both
exogenous and endogenous NO can induce apoptosis via a
mitochondria-dependent mechanism [24,25]. Studies
demonstrated that incubation of human articular chondro-
cytes with the NO donor sodium nitroprusside (SNP) induced
events characteristic of apoptosis, including increasing
caspase-3 and caspase-7 expression and downregulating
Bcl-2 expression [25]. Further examination of the
mechanisms by which SNP induces apoptosis illustrated that
SNP induced DNA fragmentation, cytoskeletal remodeling,
mitochondrial dysfunction, caspase activation, and cyto-
chrome c release [26], all of which are hallmarks of
apoptosis. Treatment with a NO scavenger significantly
decreased multiple aspects of SNP-induced cell damage
[26], once again demonstrating the pleiotropic effects of NO.
Interestingly, del Carlo and Loeser [12] found that incubation
with NO alone does not induce apoptotic cell death in
chondrocytes. In these experiments, incubation of chondro-
cytes with the NO donors SNP and 3-morpholiosydnonimine
(SIN-1), as well as the ROS peroxynitrite, all induced
apoptosis. However, both SNP and SIN-1 also generate
ROS and are not considered to be sources of pure NO.
Specifically, SIN-1 generates superoxide in addition to NO
[27,28], which can then interact with NO to generate
peroxynitrite. In support of this, treatment with either
peroxynitrite or superoxide scavengers resulted in protection
against apoptosis caused by incubation with SIN-1 but not
with SNP. Intriguingly, incubation with diazeniumdiolates
(NOC compounds), which are reliable sources of NO, did not
cause cell death and the NOC compounds protected against
oxidative stress, perhaps by suppressing chondrocyte energy
metabolism. This study demonstrated that both NO and ROS
are required to induce apoptosis, suggesting that NO alone
may have beneficial effects in chondrocytes [12].
Other studies on the effect of NO on chondrocyte apoptosis
have focused on the role of apoptosis in terminal differen-
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Figure 1
Expression patterns of NOS enzymes in chick growth plate chondrocytes. Longitudinal sections through 8-week-old proximal tibia were
immunostained with the antibodies listed and counterstained with Alcian Blue. The upper panels represent the proliferative zone and lower ones
the hypertrophic region of the growth plate. (a,b) Control section, (c,d) eNOS, (e,f) nNOS (note that the arrow indicates positively stained
hypertrophic chondrocytes), (g,h) iNOS, (i,j) anti-nitrocysteine, (k,l) anti-nitrotyrosine (arrow points to an accumulation of nitrosylated and nitrated
products). eNOS, endothelial nitric oxide synthase; iNOS, inducible nitric oxide synthase; nNOS, neuronal nitric oxide synthase. Reproduced with
permission from Teixeira and coworkers [15].tiation, again illustrating a nonpathological role for NO in
development. An increase in inorganic phosphate was shown
to induce apoptosis in terminally differentiated epiphyseal
chondrocytes [29]. Subsequent studies demonstrated that
inorganic phosphate increased both nitrate and nitrite
concentrations, and this increase was attenuated when either
NOS activity or phosphate transport was inhibited. In
addition, inorganic phosphate increased caspase-3 activity
and decreased the mitochondrial membrane potential,
whereas NOS inhibitors maintained mitochondrial function,
illustrating that NO mediates phosphate-dependent chondro-
cyte apoptosis [29].
Effects of reactive oxygen and nitrogen
species on chondrocytes and other cell types
ROS have been shown to have deleterious effects on cells
and to contribute to chondrocyte death. Davies and
colleagues [30] demonstrated that OA cartilage has
significantly more DNA damage than normal cartilage, and
that this damage was mediated by IL-1 and, ultimately, by
ROS. Porcine articular cartilage was harvested from normal
tissue and compared with cartilage harvested from OA tissue
and the number of single-stranded and double-stranded DNA
breaks was analyzed. In cells from healthy cartilage, increas-
ing concentrations of IL-1 correlated with increasing NO
concentrations and increasing DNA damage. The increase in
DNA damage was attenuated by incubation with the specific
iNOS inhibitor 1400W and the superoxide scavenger SOD,
suggesting that superoxide may have a role in generating
DNA breaks. It is not clear, however, what effect DNA
damage has on OA cells and the disease process. The
authors suggested that DNA damage could alter transcription
by increasing errors, which could result in dysfunctional
proteins, or alternatively by inhibiting the binding of trans-
cription factors to promoter regions [30].
There is some evidence that the degenerative activity
attributed to an increase in NO concentration could be a
result of an increase in the concentration of RNOS. Clancy
and coworkers [31] demonstrated that NO and peroxynitrite
have opposing effects on nuclear factor-κB (NF-κB)
activation in chondrocyte cultures. The transcription factor
NF-κB is activated rapidly in response to inflammatory stimuli
such as IL-1β and TNF-α and upregulates the transcription of
a number of genes involved in cartilage degradation including
iNOS, matrix metalloproteinases and COX-2, as well as IL-1β
and TNF-α. Inactive NF-κB is sequestered in the cytoplasm
by its inhibitor IκB. Upon activation, IκB is phosphorylated
and degraded, which allows NF-κB to translocate to the
nucleus and bind to its target DNA sequences. When bovine
chondrocytes were incubated with IL-1β, 40% of the cells
had active NF-κB, as visualized by positive immunostaining
for a NF-κB subunit in the nucleus (Figure 2). When cells
were treated with IL-1β and the NO donor S-nitrosocysteine
ethyl ester, the number of cells with nuclear NF-κB
decreased to 5%. However, incubation with IL-1β and
peroxynitrite resulted in an increase in cells with activated
NF-κB from 40% to 73%, illustrating opposing effects of NO
and ROS (Figure 2). These experiments suggest that NO is
not required for immediate activation of NF-κB and suggest
that its catabolic activity could be mediated in part through
peroxynitrite [31].
Another group analyzed the differential roles of hydrogen
peroxide and superoxide in IL-1-induced NF-κB activation.
Mendes and colleagues [32] found that IL-1 stimulation
resulted in an increase in both hydrogen peroxide and
superoxide in bovine articular chondrocytes, although only
superoxide was required for NF-κB activation and iNOS
expression. This conclusion is supported by the fact that
SOD inhibited IL-1-induced IκB degradation. Like Clancy and
coworkers [31], this group also found that NO alone inhibits
NF-κB activation and iNOS expression [33], but they
suggested that because the concentration of NO immediately
after IL-1 stimulation appeared to be quite low, it was unlikely
that significant quantities of peroxynitrite were generated.
This led them to suggest that peroxynitrite is not likely to be
required for NF-κB activation in chondrocytes. However,
these results do not exclude the possibility that peroxynitrite
is able to activate NF-κB, merely that it may not be required.
These results clearly demonstrate the difficulty in teasing out
the specific roles played by both NO and ROS in order to
determine their involvement in IL-1-induced NF-κB activation.
Peroxynitrite also helps perpetuate the inflammatory process
in mesenchymal progenitor cells (MPCs), which are used as a
model of cartilage and cartilage repair cells. Whiteman and
coworkers [34] used MPCs to investigate the cellular role of
peroxynitrite-modified collagen-II, a biomarker discovered in
the serum of patients with both OA and rheumatoid arthritis.
The authors showed that the addition of peroxynitrite-
modified collagen-II to MPC cultures induced both iNOS
expression and cyclo-oxygenase (COX)-2 synthesis and that
specific iNOS and COX-2 inhibitors blocked this synthesis.
Furthermore, the investigators demonstrated that this up-
regulation was caused by the activation of NF-κB via
mitogen-activated protein kinase signaling through p38 and
ERK1/2. Whiteman and coworkers [34] suggest that this
newly identified proinflammatory pathway may be a target for
the development of new therapies for the inflamed joint,
reiterating the complexity of NO signaling and the need for
continuing research to more fully elucidate the role of NO and
its derivatives in cellular physiology and pathophysiology.
Role of nitric oxide in other cell types in the
joint
Although there is experimental evidence to suggest a
catabolic function for NO in the joint, there is also evidence
that NO and its derivatives may play a protective role in
chondrocytes. In addition, NO has beneficial functions in
other tissues, and these activities could potentially occur in
chondrocytes as well.
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L-arginine injected into animals with dorsal wounds
significantly increased both wound-breaking strength and
collagen deposition compared with animals injected with
saline, although there was no change in plasma NO concen-
tration [35]. NO was also shown to enhance collagen syn-
thesis in human tendon cells in vitro. When cells harvested
from the torn edges of tendons from patients undergoing
rotating cuff surgery were transfected with an adenovirus
containing the gene for iNOS (Ad-iNOS) or treated with the
NO donor S-nitroso-N-acetylpenicillamine (SNAP), total
protein and collagen synthesis was enhanced, although
higher doses did inhibit collagen synthesis [36]. These
findings were supported by a small randomized double-blind
clinical trial in which the same group found that application of
a patch containing the NO donor glyceryl trinitrate
significantly improved outcomes in patients with supra-
spinatus tendonopathy compared with patients who received
placebo [37]. This illustrates that the benefits of exogenous
NO in tendons is not simply an in vitro effect.
Muscará and colleagues [38] also demonstrated that
exogenous NO is beneficial in a rat wound healing model.
The investigators compared the effects of the cyclo-
oxygenase-inhibiting nitric oxide donating (CINOD) agent
naproxcinod to its parent compound naproxen on wound
healing. Despite inhibiting prostaglandin synthesis to the
same extent as naproxen, naproxcinod significantly enhanced
collagen deposition at the wound site whereas naproxen
decreased collagen deposition, illustrating once again that
exogenous NO may help to increase collagen deposition
under some conditions. These studies suggest that perhaps
there are some conditions in which NO donors could induce
collagen deposition in chondrocytes.
Studies have also suggested that exposure to low levels of
NO could be protective against subsequent oxidative stress.
Tai and coworkers [39] demonstrated that NO helps to
regulate osteoblast activity. Pretreatment of cultured osteo-
blasts with a low concentration of the NO donor SNP
(0.3 mmol/l) resulted in no change in cell viability and only a
slight increase in cellular NO concentration. Treatment with a
high concentration of the NO donor SNP (2 mmol/l) induced
cellular NO and ROS and as well as cell death via apoptosis.
However, when osteoblasts were pretreated with the low
concentration of SNP and then subjected to the high
concentration, cell viability was significantly increased and
apoptosis was significantly decreased compared with no
pretreatment. This protection was probably mediated via
JNKc-Jun-mediated regulation of Bcl-2 gene expression and
translocation to the mitochondria. Interestingly, pretreatment
with low concentrations of SNP enhanced the increases in
both NO and ROS, demonstrating that the pretreatment is
not merely suppressing cellular oxidative stress but in some
way protecting against damage. These experiments again
illustrate the complexity of the role played by NO in cellular
metabolism as well as the varied responses to ROS in
different cell types.
Role of nitric oxide in nociception and pain
As mentioned above, pain is the major determinant in
functional disability caused by OA [40]. NO and RNOS are
both involved in perception and reduction of pain, and
therefore could be a target for the management of pain in OA.
Hancock and Riegger-Krugh [41] recently reviewed several
potential mechanisms that may explain the role played by NO
in pain reduction in patients with OA: the blood-flow pathway
is normalized in the presence of NO, which may help to
decrease ischemic pain; the nerve transmission pathway,
which decreases the irritation of the nerves in the synovium,
bone, and soft tissues; the opioid receptor pathway, which
might stimulate the body’s normal pain reduction pathways;
and the anti-inflammation pathway. The authors concluded
that small amounts of transiently produced NO, perhaps
produced by endothelial NOS, could potentially decrease the
pain associated with OA. However, like the role of NO in the
Available online http://arthritis-research.com/supplements/10/S2/S2
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Figure 2
Effects of peroxynitrite and the NO donor SCNEE on IL-1β stimulated NF-κB (p65) nuclear translocation. NF-κB, nuclear factor-κB; NO, nitric
oxide; PN, peroxynitrite; SCNEE, S-nitrosocysteine ethyl ester. Reproduced with permission from Clancy and coworkers [31].OA disease process, research in this field is still ongoing and
there are many outstanding questions.
In addition to NO, RNOS also plays a role in pain and
nociception. Wang and coworkers [42] showed that super-
oxide is involved in pain deriving from inflammation. Injection
of a SOD mimetic (M40403) blocked the inflammation,
edema, and hyperalgesia associated with carrageenan
injection. In addition, the formation of peroxynitrite was also
inhibited after injection of M40403, suggesting that both
superoxide and peroxynitrite play a role in the development of
inflammation and pain. Subsequent experiments by the same
laboratory showed that the development of morphine-induced
tolerance is associated with increased proinflammatory
cytokine production as well as oxidative DNA damage [43].
Inhibition of NO synthesis or the scavenging of superoxide
both block the development of morphine-induced tolerance,
suggesting that peroxynitrite is involved. This hypothesis was
confirmed using a peroxynitrite-decomposition catalyst, which
blocked the antinociceptive tolerance response, suggesting
once again that decreasing the production of peroxynitrite
could help to ameliorate chronic pain.
Peroxynitrite appears to perpetuate the inflammatory process at
least in part by helping to induce COX-2 activity. When
superoxide or peroxynitrite was injected into rats, the animals
developed thermal hyperalgesia, which is associated with
tissue damage and inflammation. The response was blocked by
the addition of the NOS inhibitor NG-nitro-L-arginine methyl
ester (L-NAME), or a peroxynitrite-decomposition catalyst,
suggesting that peroxynitrite was responsible for the effect
[44]. Further experiments demonstrated that this led to the
activation of NF-κB, which enhanced the expression of the
COX-2 but not the COX-1 enzyme. The response was blocked
in a dose-dependent manner by the nonselective COX inhibitor
indomethacin, the selective COX-2 inhibitor NS398, and an
anti-prostaglandin E2 antibody. These results confirm that
peroxynitrite does mediate hyperalgesia associated with
inflammation through the COX-prostaglandin E2 pathway.
Conclusion
The role played by NO in the function of normal and
pathological joints is still incompletely understood. Although it
is clear that NO and RNOS both play a role in the OA
disease process, as well as in the perception of pain, studies
analyzing the effects of NO-donating agents in both
chondrocytes and other cell types are providing insights that
suggest that there are also protective functions for NO and
its redox derivatives in individual cell types. Future research
into the role played by NO in OA and the utility of NO-
donating agents may provide a new therapeutic option for the
treatment of OA with an improved risk profile compared with
currently available therapies.
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